Valuation: Nexstim Oyj

Market Cap 7.74Cr 8.95Cr 7.23Cr 6.63Cr 12Cr 852.01Cr 13Cr 85Cr 33Cr 427.05Cr 34Cr 33Cr 1.41TCr P/E 2026 *
79.9x
P/E 2027 * 35.5x
Enterprise Value 7.53Cr 8.71Cr 7.04Cr 6.45Cr 12Cr 828.91Cr 12Cr 83Cr 32Cr 415.47Cr 33Cr 32Cr 1.37TCr EV / Sales 2026 *
5.93x
EV / Sales 2027 * 4.58x
Free-Float
58.2%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 50 11/02/2020
Director of Finance/CFO 40 11/02/2020
Chief Tech/Sci/R&D Officer 65 01/01/2008
Director TitleAgeSince
Director/Board Member 64 11/11/2019
Chairman 63 11/11/2019
Director/Board Member 55 01/05/2021
Change 5-day change 1-year change 3-year change Capi.($)
-6.90%-5.73% - - 8.95Cr
+2.41%+3.43%+28.93%+8.48% 22TCr
+2.39%+5.02%+2.09%-20.03% 14TCr
+1.36%+7.21%-19.42%+24.57% 13TCr
+0.02%+5.52%-52.19%-3.43% 7.15TCr
+0.45%+4.24%+14.51%+15.07% 5.17TCr
+1.05%+7.19%-14.90%-17.86% 5.08TCr
+3.28%+5.49%+27.35%+14.37% 4.12TCr
+1.79%+7.83%+44.69%+39.33% 3.99TCr
+2.08%+5.51%-0.32%-2.91% 3.24TCr
Average +0.79%+5.55%+3.42%+6.40% 8.72TCr
Weighted average by Cap. +1.79%+5.17%+4.10%+5.05%

Financials

2026 *2027 *
Net sales 1.27Cr 1.47Cr 1.19Cr 1.09Cr 2.05Cr 139.73Cr 2.08Cr 14Cr 5.46Cr 70Cr 5.51Cr 5.39Cr 231.54Cr 1.61Cr 1.86Cr 1.5Cr 1.38Cr 2.59Cr 177.14Cr 2.64Cr 18Cr 6.92Cr 89Cr 6.99Cr 6.84Cr 293.53Cr
Net income 10L 11.56L 9L 9L 16.11L 11Cr 16.37L 1.1Cr 43L 5.51Cr 43.41L 42.46L 18Cr 22L 25.43L 20.54L 18.85L 35.45L 24Cr 36.01L 2.41Cr 94.61L 12Cr 95.51L 93.42L 40Cr
Net Debt -21L -24.28L -19.61L -17.99L -33.84L -23Cr -34.37L -2.3Cr -90.31L -12Cr -91.17L -89.17L -38Cr -37L -42.77L -34.55L -31.7L -59.62L -41Cr -60.56L -4.05Cr -1.59Cr -20Cr -1.61Cr -1.57Cr -67Cr
Logo Nexstim Oyj
Nexstim Oyj is a Finland-based medical technology company. It is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Company’s systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-